ECCO 2024

The quest for predictive markers goes on...

S1P-Modulators from a safety perspective

Real-world data from a H2H-study on Vedolizumab vs.…

Primary sclerosing cholangitis – lessons from a large…

A spotlight on the PROFILE study

Treatment targets in 2024 - a silent revolution

Combination of different drug classes - risks and…

Finally here: controlled trials in surgery!

IL-23 in UC

Ustekinumab first, anti-p19 second?

Next chapter in S1P- and JAK-inhibition

Obefazimod & IL23R-CAR-Tregs - new molecules in focus

Results of the phase II PIZZICATO (ritlecitinib &…

Tregs - a treatment for the future?

Mirikizumab in moderate to severe Crohn’s disease:…

Darvadstrocel for complex perianal fistulas and Crohn’s…

VIVID 1: Mirikizumab in Crohn's Disease

VIVID 1: Comparison of mirikizumab with ustekinumab in…

Changing the PROFILE of how we treat CD

Mirikizumab vs Ustekinumab

Mirikizumab in crohn's disease

VIVID 1- Comparação do Mirikizumab com o Ustecinumab na…

Resultaten van de fase 2 PIZZICATO (ritlecitinib &…

PIZZICATO - neue JAKs für Morbus Crohn

Mirikizumab bei Morbus Crohn

Mirikizumab στη θεραπεία της μέτριας προς βαρειά NC:…

The efficacy of biologics and small molecules in…

Long term outcome of Obefazimod in UC

Risankizumab & guselkumab in ulcerative colitis

Mirikizumab in anti-TNF failures with UC

VTX002 (S1P-modulator) & obefazimod in ulcerative…

VTX002 (S1P-Modulator) & Obefazimod bei Colitis…

Risankizumab & Guselkumab bei Colitis Ulcerosa

Leki biologiczne i małocząsteczkowe w terapii…

lange-termijns uitkomst van obefazimod in UC

Therapy in transition

Still a long road ahead in standards of care in IBD –…

Marzenia a rzeczywistość – wyniki ankiety E-QUALITY na…

Therapie im Umbruch

Biomarker for biological loss of response in CD?

Changing treatment paradigm in CD

Early intervention in Crohn´s disease therapy

Results from the PROFILE-trial

PROFILE: practice-changing results

PROFILE: Biomarkers not successfull for therapy…

Allogenic mesenchymal stem cells for complex fistula in…

Cambiano i paradigmi di trattamento nelle malattie di…

Risultati dallo studio PROFILE

Biomarker for biological loss of response in CD?

PROFILE: Biomarker nicht erfolgreich zur Prädiktion der…

Intervenção terapêutica precoce na doença de Crohn

Injection de cellules souches mesenchimateuses…

Towards the proactive management of AS-UC responding to…

Vers un traitement plus agressif de la colite aigüe…

Personalized treatment in IBD: reality or hype?

Therapy in transition

Use of CAR-Tregs in IBD: preclinical data

HD-WLE with segmental reinspection is not inferior to…

Immunohomöstase durch regulatorische CAR-T-Zellen!?

Utilizzo di cellule CAR Tregs nelle MICI: dati…

HD-WLE με επανεξέταση των τμημάτων δεν υπολείπεται της…

gepersonaliseerde aanpak van IBD: realiteit of hype?

No changes to surgical techniques for ileosecal…

MIRACLE project: Avoidance of protective Ileostomy

Randomised clinical trials finally coming to IBD…

End of the Kono-S legend!

Extended mesenterectomy is not superior to mesenteric…

Colectomy and the natural history of PSC – lessons form…

MIRACLE-Projekt: Verzicht auf protektive Ileostomie

Kolektomia a historia naturalna PSC – czy istnieje…

Implicazioni della proctocolectomia in pazienti affetti…

La fin de la legende du Kono-S!

Los ensayos clínicos aleatorizados llegan a la cirugía…

Molecular effects of IL-23p19 blockade

Molekulare Effekte der IL-23p19-Blockade